ArticleBMC veterinary research2017
Evaluation of six serological ELISA kits available in Italy as screening tests for equine infectious anaemia surveillance.
Article in BMC veterinary research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Evaluation of synthetic peptides derived from glycoproteins gp45 and gp90 as candidates for the immunodiagnosis of equine infectious anemia.Veterinary research communications · 2026Article
- Vector-borne diseases-knowledge maps.EFSA journal. European Food Safety Authority · 2026Article
- Whole genome sequencing and phylogenetic analysis of the equine infectious anemia virus associated with 2017 Spain outbreaks.BMC veterinary research · 2025Article
- Equine infectious anemia in Brazilian equestrian tourism horses: serological, molecular, and biochemical assessment showing high EIAV seroprevalence and elevated gamma-glutamyl transferase (GGT) levels.Veterinary research communications · 2025Article
- Development of a colloidal gold immunochromatographic strip to detect equine infectious anemia virus.Virology journal · 2025Article
- Comparative Evaluation of a Multistrain Indirect ELISA Targeting Anti- p26 and gp45 Antibodies for EIAV Detection.Pathogens (Basel, Switzerland) · 2025Article
- Global prevalence and risk factors of equine infectious anemia: A systematic review and meta-analysis.Veterinary world · 2025Review
- Serodiagnosis of equine infectious anemia by indirect ELISA based on a novel synthetic peptide derived from gp45 glycoprotein.Veterinary research communications · 2025Article
- Equine Infectious Anaemia: The Active Surveillance of an Entire Equid Population Reduces the Occurrence of the Infection.Transboundary and emerging diseases · 2024Article
- Development and evaluation of a blocking ELISA for serological diagnosis of equine infectious anemia.Applied microbiology and biotechnology · 2023Article
- Identification and genetic characterization of equine infectious anemia virus in Western Balkans.BMC veterinary research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundELISAs are known to have a higher diagnostic sensitivity than the agar gel immunodiffusion (AGID) when employed for serological diagnosis of equine infectious anaemia (EIA). For this purpose, an "in-house" and five commercial ELISAs available in Italy were assessed by the National Reference Centre for EIA for their analytic specificity (Sp); precocity, defined as capability of detecting first antibodies produced during a new infection; precision based on repeatability and reproducibility, estimated from the coefficient of variation (CV); accuracy, estimated from multiple K and relative Sp and sensitivity (Se). Two serum panels, positive for non-equine retroviruses and the most frequent equine viruses, were employed to measure analytic Sp. ELISA precocity was also compared to that of one "in-house" and three commercial AGID kits, employing a panel of sera, collected weekly from horses infected with modified EIA viruses. Precision and accuracy were defined using results of a panel containing positive and negative sera examined in an inter-laboratory trial with the participation of the ten Official Laboratories. Furthermore, a questionnaire was used to assess the appropriateness of each kit for routine use.
resultsAnalytic Sp was 100%, while the 75th percentile of CVs for positive sera varied from 0.4% to 12.73% for repeatability and from 1.6% to 44.87% for reproducibility. Although CV of the negative serum was constantly high, its outcome was unaltered. Relative Se ranged from 98.2% to 100%, relative Sp was constantly 100% and multiple K ranged from 0.95 to 1. Precocity differed among the assays: three kits detected 4.8% and 42.9% positive samples on 21 days post infection (dpi), all assays detected positive samples on 28 dpi, between 47.6% and 95.2%. Precocity of ELISAs was superior to that of the AGIDs except for two assays. In view of the feedback obtained from the questionnaires, all kits were considered appropriate for routine use.
conclusionAll ELISAs having high Se and precocity are preferable as a screening test in EIA surveillance programmes to the AGID tests examined. These two tests can be incorporated in a serial diagnostic pathway to improve the efficacy of a surveillance plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.